Annales pharmaceutiques francaises最新文献

{"title":"Urinary cytomegalovirus excretion: The unresolved issues","authors":"","doi":"10.1016/j.pharma.2024.03.004","DOIUrl":"10.1016/j.pharma.2024.03.004","url":null,"abstract":"<div><p>Cytomegalovirus (CMV) excretion in urine is frequently observed in clinical practice. However, the specific circumstances and pathophysiological mechanisms underlying this shedding remain largely unknown. Here, we address some of the key questions regarding urinary CMV excretion, focusing on new hypotheses raised by recent advances in the field. Cellular origins of CMV shedding, clinical contexts of occurrence, systemic spread of the virus <em>versus</em> compartmentalization in the urinary tract, and clinical impact are successively discussed.</p></div><div><p>Le cytomégalovirus (CMV) est fréquemment détecté dans l’urine mais les circonstances cliniques et les mécanismes physiopathologiques qui sous-tendent cette virurie restent mal compris. Dans cette revue, nous cherchons à répondre aux principales questions soulevées par cette excrétion urinaire de CMV, en appréhendant successivement: l’origine cellulaire de l’excrétion virale au sein de l’arbre urinaire, le contexte clinique sous-jacent, la distinction entre diffusion systémique du virus et compartimentation et l’impact clinique de ces viruries à CMV.</p></div>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"82 5","pages":"Pages 755-761"},"PeriodicalIF":1.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140139838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic effects of stevia aqueous extract alone or in combination with metformin in induced polycystic ovary syndrome rats: Gene expression, hormonal balance, and metabolomics aspects.","authors":"A Saedi, S Zarei, M Vatanparast, M R Hajizadeh, R Hosseiniara, O S Esmaeili, M Mohammad-Sadeghipour, Z Mirzaei, M Mahmoodi","doi":"10.1016/j.pharma.2024.08.008","DOIUrl":"10.1016/j.pharma.2024.08.008","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to assess the individual and combined effects of SAE and Met on the expression of genes related to insulin signaling, oxidative stress, hormonal imbalance, insulin resistance, and dyslipidemia in rats with induced PCOS.</p><p><strong>Methods: </strong>The estrous cycle of 50 adult Wistar female rats was monitored through vaginal smears. Subsequently, the rats were randomly assigned into five groups of 10, including control (receiving 1ml of carboxymethyl cellulose for 49 days), induction (letrozole at 1mg/kg/d for 21 days), SAE, Met, and SAE/Met. SAE and Met were orally administered at doses of 400mg/kg/d and 250mg/kg/d on day 22 and continued for an additional 28 days. Vaginal smears were analyzed, and gene expression levels of GLUT4, SIRT1, TNF-α, and INSR were evaluated using RT-qPCR. Antioxidant parameters were assessed using detection kits.</p><p><strong>Results: </strong>Treatment with SAE and Met restored a regular estrous cycle pattern in PCOS rats. Furthermore, SAE and Met treatment improved hormonal balance, dyslipidemia, and hyperglycemia in the rats. Administration of SAE and Met significantly elevated levels of antioxidant enzymes SOD and GPx in ovarian tissue (P<0.001). Additionally, mRNA levels of GLUT4, SIRT1, and INSR were significantly increased in ovarian tissue following SAE and Met treatment, while TNF-α gene expression decreased significantly (P<0.0001).</p><p><strong>Conclusion: </strong>The findings suggest that SAE and Met aqueous extract exert protective effects on letrozole-induced PCOS in rats by modulating gene expression associated with insulin signaling and oxidative stress.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142054789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk analysis applied to the process of managing medical single use devices in a hospital pharmacy department.","authors":"Aymen Ben Salem, Fatma Sellami, Ahlem Ben Cheikh Brahim, Yosr Krichen, Aimen Abbassi","doi":"10.1016/j.pharma.2024.08.006","DOIUrl":"10.1016/j.pharma.2024.08.006","url":null,"abstract":"<p><strong>Introduction: </strong>During the COVID-19 pandemic, single use medical devices' supply (SUMD) was marked by repetitive and unforeseen interruptions. The present study aimed to determine the risks related to the processes of management of medical devices in our CHU according to a method of failure mode, effect and criticality analysis (FMECA).</p><p><strong>Methods: </strong>Qualified healthcare professionals were recruited to form a multidisciplinary consensus committee. By analyzing the process map, all failure modes, causes and consequences were identified through brainstorming meetings. They were then classified taking into account the criticality index (CI) calculated according to three parameters: frequency, severity, and detectability. The prioritization was carried out by considering the mean and the median values of the CI as limits. Corrective and preventive actions were then proposed.</p><p><strong>Results: </strong>A total of 49 failure modes were identified, accumulating 4466 criticality points. The most critical step is that relating to the inter-depot order with a CI equal to 783 points. An action plan was developed, allows us to control 64% of the overall criticality of the risks linked to the process. Three main lines of action have been proposed: continuous training, especially for managerial and administrative tasks, logistical improvement (architectural reorganization and implementation of systems for securing the circuit of SUMDs) and support for the digitization of hospital pharmacy.</p><p><strong>Conclusion: </strong>The FMECA is a consensual method, which makes it possible to propose actions in order to reduce the risks linked to the process of managing medical devices. Optimizing the estimation of needs, strengthening communication with stakeholders and securing the circuit are essential to guarantee the availability of SUMDs for the benefit of the patient.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142046165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Harmonization of regulatory frameworks for medical devices in BRICS countries: A path to enhanced trade and investment.","authors":"Himanshu Pawar, Mital Patel","doi":"10.1016/j.pharma.2024.08.007","DOIUrl":"10.1016/j.pharma.2024.08.007","url":null,"abstract":"<p><p>The study is designed to advocate for a harmonized medical device regulatory framework throughout the BRICS countries with a view to facilitating trade, attracting investments and safeguarding patients' health. The development of the medical devices industry in BRICS countries is impeded by a lack of standardized regulation. A harmonized framework would facilitate the approval process, promotion of innovation and wider access for patients to modern medical technologies. The paper analyses existing regulatory frameworks for medical devices in BRICS countries and identifies their strengths and weaknesses. Specific measures to harmonize such as standardization of technology, interoperability and the implementation of transparent licensing procedures are also proposed. The study indicates that a joint committee should be set up to supervise legal harmonization, standardization of classification and development of specific technical specifications. It also provides information about the regulatory framework in different countries, such as Brazil, Russia, India, China and South Africa, on classification of medical devices. Report emphasizes the need for a harmonized regulatory framework to rapidly introduce new healthcare technologies. It suggests that the BRICS countries can create a more conducive environment for the medical device industry, ultimately benefiting patients, manufacturers and the overall healthcare system by aligning their legislation.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142046204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Évaluation de la faisabilité du dispositif d’auto-administration des médicaments par le patient dans un centre hospitalier universitaire : audits de pratique et recommandations pour une mise en œuvre sûre","authors":"Cyril Baudrier ,&nbsp;Victoire Petitcuenot ,&nbsp;Nacima Oussedik ,&nbsp;William Champeau ,&nbsp;Rouba Alarab ,&nbsp;Anne-Laure Lefebvre ,&nbsp;Yara Rahma ,&nbsp;Cecile Bottois ,&nbsp;Ornella Conort","doi":"10.1016/j.pharma.2024.08.004","DOIUrl":"10.1016/j.pharma.2024.08.004","url":null,"abstract":"&lt;div&gt;&lt;div&gt;En 2022, la HAS a émis des recommandations sur l’auto-administration des médicaments, destinée aux patients volontaires en hospitalisation, sous accord médical. L’objectif de notre étude est d’évaluer les pratiques liées à la gestion des médicaments dans notre établissement afin de proposer des recommandations pour une mise en œuvre sûre du dispositif d’auto-administration des médicaments. Une étude monocentrique prospective a été menée entre janvier et juin 2023. Deux audits ont été réalisés auprès des patients et des infirmier(e)s à l’aide de questionnaires basés sur les recommandations de la HAS. Sur un total de 207 patients, avec un âge moyen de 59,6 ans, 56 % étaient favorables à gérer les traitements initiés à l’hôpital. Parmi ceux ayant des traitements habituels, 62 % étaient favorables pour continuer à les gérer à l’hôpital. Dans les unités d’hospitalisation de semaine, 92 % des patients étaient favorables à la gestion de leurs traitements habituels, et 75 % à ceux initiés à l’hôpital. Parmi les 26 infirmier(e)s interrogé(e)s, 71 % ont noté l’autonomie des patients pour la prise médicamenteuse dans les transmissions narratives, 88 % ont vérifié la prise médicamenteuse en auto-administration, et 96 % l’ont tracée informatiquement. Le dispositif d’auto-administration des médicaments est envisageable dans notre établissement, notamment dans les unités d’hospitalisation de semaine avec des patients ayant une bonne connaissance de leurs traitements. Actuellement, les infirmier(e)s évaluent et assurent la traçabilité de l’autonomie du patient sans outils spécifiques. Pour garantir le succès de cette nouvelle approche, une collaboration entre les professionnels de santé est essentielle, avec un rôle central du pharmacien.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;The French Health Authority recently published guidelines about patient self-administration of medications for voluntary hospitalized patients under medical supervision. This study aimed to assess medication management practices in our hospital and provide recommendations for self-administration medication. A prospective monocentric study was performed from January to June 2023, involving patient and nurse surveys based on the guidelines from the French Health Authority. A total of 207 patients participated in the survey, with a mean age of 59.6&lt;!--&gt; &lt;!--&gt;years. Among them, 56% were inclined to self-manage treatments initiated during hospitalization. Among patients with regular treatments, 62% were inclined to self-manage them in the hospital. In weekday hospitalization units, 92% of patients were inclined to self-manage their regular treatments, and 75% of those initiated during hospitalization. Among the 26 surveyed nurses, 71% reported patient autonomy for taking drugs in narrative transmissions, and 88% verified medication intake through self-administration, while 96% digitally traced it. The concept of self-administration of medication appears promising, especially within weekday hospitalizat","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"82 6","pages":"Pages 1186-1200"},"PeriodicalIF":1.0,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141999377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular disease and thrombosis: Intersections with the immune system, inflammation, and the coagulation system.","authors":"Shivam Rajput, Rishabha Malviya, Saurabh Srivastava, Irfan Ahmad, Safia Obaidur Rab, Prerna Uniyal","doi":"10.1016/j.pharma.2024.08.005","DOIUrl":"10.1016/j.pharma.2024.08.005","url":null,"abstract":"<p><p>The coagulation and immune system, both essential physiological systems in the human body, are intricately interconnected and play a critical role in determining the overall health of patients. These systems collaborate via various shared regulatory pathways, such as the Tissue Factor (TF) Pathway. Immunological cells that express TF and generate pro-inflammatory cytokines have the ability to affect coagulation. Conversely, coagulation factors and processes have a reciprocal effect on immunological responses by stimulating immune cells and regulating their functions. These interconnected pathways play a role in both preserving well-being and contributing to a range of pathological disorders. The close relationship between blood clotting and inflammation in the development of vascular disease has become a central focus of clinical study. This research specifically examines the crucial elements of this interaction within the contexts of cardiovascular disease and acute coronary syndrome. Tissue factor, the primary trigger of the extrinsic coagulation pathway, has a crucial function by inducing a proinflammatory reaction through the activation of coagulation factors. This, in turn, initiates coagulation and subsequent cellular signalling pathways. Protease-activated receptors establish the molecular connection between coagulation and inflammation by interacting with activated clotting factors II, X, and VII. Thrombosis, a condition characterised by the formation of blood clots, is the most dreaded consequence of cardiovascular disorders and a leading cause of death globally. Consequently, it poses a significant challenge to healthcare systems. Antithrombotic treatments efficiently target platelets and the coagulation cascade, but they come with the inherent danger of causing bleeding. Furthermore, antithrombotics are unable to fully eliminate thrombotic events, highlighting a treatment deficiency caused by a third mechanism that has not yet been sufficiently addressed, namely inflammation. Understanding these connections may aid in the development of novel approaches to mitigate the harmful mutual exacerbation of inflammation and coagulation. Gaining a comprehensive understanding of the intricate interaction among these systems is crucial for the management of diseases and the creation of efficacious remedies. Through the examination of these prevalent regulatory systems, we can discover novel therapeutic approaches that specifically target these complex illnesses. This paper provides a thorough examination of the reciprocal relationship between the coagulation and immune systems, emphasising its importance in maintaining health and understanding disease processes. This review examines the interplay between inflammation and thrombosis and its role in the development of thrombotic disorders.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142003492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aqueous eye drop formulations: Cyclodextrins as enabling excipients","authors":"Frédéric Pilotaz ,&nbsp;Thorsteinn Loftsson","doi":"10.1016/j.pharma.2024.08.003","DOIUrl":"10.1016/j.pharma.2024.08.003","url":null,"abstract":"<div><div>Cyclodextrins are enabling pharmaceutical excipients that solubilize and stabilize drugs in aqueous formulations. Cyclodextrins possess very favorable pharmacokinetic and toxicological profiles and are commonly used in marketed drug products for oral and parenteral administration. However, their use in ophthalmic products is still very limited. Cyclodextrins have a broad range of physical properties that are specifically appropriate for designing topical ophthalmic dosage forms. Additionally, both the regulatory and intellectual property environments have been cleared over the last years and should foster their use for designing new drugs for ophthalmic use.</div></div><div><div>Les cyclodextrines sont des excipients permettant la solubilisation et la stabilisation de médicaments dans les formes pharmaceutiques aqueuses. Les cyclodextrines possèdent des profils pharmacocinétiques et toxicologiques très favorables et sont couramment utilisées dans des médicaments commercialisés pour l’administration orale et parentérale. Toutefois, leur utilisation dans les produits ophtalmiques est encore très limitée. Les cyclodextrines possèdent un large spectre de propriétés physiques qui est particulièrement adapté pour la conception de formes pharmaceutiques à usage topique ophtalmique. Enfin, leur environnement réglementaire ainsi que celui de la propriété intellectuelle se sont éclaircis au cours des dernières années, ce qui devrait favoriser leur utilisation pour la conception de nouveaux médicaments à usage ophtalmique.</div></div>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"82 6","pages":"Pages 994-1007"},"PeriodicalIF":1.0,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141911557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding the side effects of chronic silodosin administration via untargeted metabolomics approach","authors":"Tugrul Cagri Akman ,&nbsp;Yucel Kadioglu ,&nbsp;Onur Senol ,&nbsp;Beyzagul Erkayman ,&nbsp;İsmail Cagri Aydin","doi":"10.1016/j.pharma.2024.08.002","DOIUrl":"10.1016/j.pharma.2024.08.002","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Precision medicine, which looks for high efficacy and low toxicity in therapies, has increased in popularity with omics technology. This work aims to discover novel and low-toxicity therapy options by examining the complex relationship between silodosin-induced side effects and the metabolomic profiles associated with its administration.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Materials and methods&lt;/h3&gt;&lt;div&gt;The plasma samples of the control group and silodosin-treated rats were analyzed by LC-Q-TOF-MS/MS. Employing XCMS and MetaboAnalyst software, MS/MS data processed to detect compounds and investigate metabolic pathways. MATLAB 2019b was used for data categorization and multivariate analysis. A thorough comparison of METLIN and HMDB databases revealed 41&lt;!--&gt; &lt;em&gt;m/z&lt;/em&gt; values with significant differences between the drug-treated and control groups (&lt;!--&gt; &lt;em&gt;p&lt;/em&gt; &lt;&lt;!--&gt; &lt;!--&gt;0.01 and fold analysis&lt;!--&gt; &lt;!--&gt;≥&lt;!--&gt; &lt;!--&gt;1.5).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;According to multivariate data analysis, 17-&lt;em&gt;β&lt;/em&gt;-estradiol, taurocholic acid, L-kynurenine, &lt;em&gt;N&lt;/em&gt;-formylkynurenine, D-glutamine, L-arginine, prostaglandin H2, prostaglandine G2, 15-keto-prostaglandin E2, calcidiol, thromboxane A2, 5′-methylthioadenosine, L-methionine and &lt;em&gt;S&lt;/em&gt;-adenosylmethionine levels changed significantly compared to the control group. Differences in the metabolisms of glycerophospholipid, tyrosine, phenylalanine, arachidonic acid, cysteine and methionine, and biosynthesis of phenylalanine, tyrosine, and tryptophan, and aminoacyl-tRNA have been successfully demonstrated by metabolic pathway analysis. According to this study, vitamin D, D-glutamine, and L-arginine supplements can be recommended to prevent side effects such as fatigue, intraoperative floppy iris syndrome, blurred vision, and dizziness in the treatment of silodosin. Silodosin treatment negatively affected the immune system by affecting the kynurenine and tryptophan metabolism pathways.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;The study is a guide for silodosin treatments that offer low side effects and high therapeutic effect within the scope of precision medicine.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Contexte&lt;/h3&gt;&lt;div&gt;La médecine de précision, qui recherche une efficacité élevée et une faible toxicité dans les thérapies, a gagné en popularité grâce à la technologie omics. Ce travail vise à découvrir de nouvelles options thérapeutiques à faible toxicité en examinant la relation complexe entre les effets secondaires induits par la silodosine et les profils métabolomiques associés à son administration.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Matériaux et méthodes&lt;/h3&gt;&lt;div&gt;Les échantillons de plasma du groupe témoin et des rats traités à la silodosine ont été analysés par LC-Q-TOF-MS/MS. Les logiciels XCMS et MetaboAnalyst ont été utilisés pour traiter les données MS/MS afin d’identifier les métabolites et d’analyser les voies métaboliques. MATLAB 2019b a été utilisé pour catégoriser les données afin d’effectuer","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":"82 6","pages":"Pages 1150-1162"},"PeriodicalIF":1.0,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141911558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A review on recent advancements in pharmaceutical technology transfer of tablets from an Indian perspective.","authors":"Kishan Singh, Nidhi Nainwal, Havagiray R Chitme","doi":"10.1016/j.pharma.2024.08.001","DOIUrl":"10.1016/j.pharma.2024.08.001","url":null,"abstract":"<p><strong>Objective: </strong>The healthcare sector is a paramount and rapidly expanding industry in India. The pharmaceutical field in India has experienced substantial growth and transformation in recent times, making significant contributions to the global healthcare market. This comprehensive review delves into the most recent innovations in pharmaceutical technology transfer (TT), particularly in the context of tablet formulations from an Indian standpoint.</p><p><strong>Significance: </strong>The pharmaceutical sector has grappled with various challenging issues, including the escalating costs of medications and the demand for patient-friendly products.</p><p><strong>Methods: </strong>In this technological progress era, various cutting-edge pharmaceutical technologies, such as artificial intelligence (AI), and 3D and 4D printing, play pivotal roles in drug development. Tablets, the most promising and widely utilized dosage form worldwide, require a sophisticated approach to TT. Achieving a successful TT necessitates a dedicated team with well-defined objectives, improved documentation, and effective communication.</p><p><strong>Results: </strong>The Indian Pharmaceutical Industry (IPI) possesses the potential to make significant contributions to the global healthcare sector. Moreover, we delve into the various phases of TT, highlighting the pivotal role of formulation development and process optimization in ensuring product quality, efficiency, and cost-effectiveness along with different models of TT. Additionally, we examine the challenges associated with TT and potential solutions, as well as the initiatives of the Indian government to bolster the Indian pharmaceutical sector's position as the \"Pharmacy of the World\".</p><p><strong>Conclusion: </strong>It is concluded that there is a need to contextualize and institutionalize the tech transfer policies for successful implementation for the benefit of the global population.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141911556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing drug bioavailability for Parkinson's disease: The promise of chitosan delivery mechanisms.","authors":"Mohammad Arshad Javed Shaikh, Gaurav Gupta, Pawan Bagiyal, Saurabh Gupta, Santosh Kumar Singh, Ramkumar Pillappan, Dinesh Kumar Chellappan, Parteek Prasher, Vikas Jakhmola, Thakur Gurjeet Singh, Harish Dureja, Sachin Kumar Singh, Kamal Dua","doi":"10.1016/j.pharma.2024.07.008","DOIUrl":"10.1016/j.pharma.2024.07.008","url":null,"abstract":"<p><p>Parkinson's disease (PD) is a widely seen neurodegenerative condition recognized by misfolded α-synuclein (αSyn) protein, a prominent indicator for PD and other synucleinopathies. Motor symptoms like stiffness, akinesia, rest tremor, and postural instability coexist with nonmotor symptoms that differ from person to person in the development of PD. These symptoms arise from a progressive loss of synapses and neurons, leading to a widespread degenerative process in multiple organs. Implementing medical and surgical interventions, such as deep brain stimulation, has enhanced individuals' overall well-being and long-term survival with PD. It should be mentioned that these treatments cannot stop the condition from getting worse. The complicated structure of the brain and the existence of a semi-permeable barrier, commonly known as the BBB, have traditionally made medication delivery for the treatment of PD a challenging endeavor. The drug's low lipophilic nature, enormous size, and peculiarity for various ATP-dependent transport mechanisms hinder its ability to enter brain cells. This article delves at the potential of drug delivery systems based on chitosan (CS) to treat PD.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141874053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}